Form 4: Aadi Bioscience Director Acquires Stock Options

Director Mohammad Hirmand acquired stock options for 45,832 shares of Aadi Bioscience, Inc. on June 12, 2024.

Summary

• Mohammad Hirmand, a director of Aadi Bioscience, Inc., filed a Form 4 on June 14, 2024, reporting a transaction.
• On June 12, 2024, Hirmand acquired stock options for 45,832 shares of Aadi Bioscience common stock at an exercise price of $1.70.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.
• Following the transaction, Hirmand directly owns 45,832 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but the director's investment could be interpreted as a sign of confidence.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting of the options is contingent upon the director's continued service, which introduces a risk if the director were to leave the company before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is tied to the director's continued service and the company's annual meeting schedule.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates